Vertex Pharmaceuticals Incorporated (VRTX) : Traders are bullish on Vertex Pharmaceuticals Incorporated (VRTX) as it has outperformed the S&P 500 by a wide margin of 6.96% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.38%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.31% in the last 1 week, and is up 10.55% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.01% and the 50-Day Moving Average is 8.4%. Vertex Pharmaceuticals Incorporated is up 15.01% in the last 3-month period. Year-to-Date the stock performance stands at -22.91%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): stock turned positive on Friday. Though the stock opened at $96.28, the bulls momentum made the stock top out at $97.07 level for the day. The stock recorded a low of $95.405 and closed the trading day at $97, in the green by 0.82%. The total traded volume for the day was 1,012,773. The stock had closed at $96.21 in the previous days trading.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.